Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | AGL | P35573 | 2/20 | 0.30 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230154 | 1.00 | DPP4 (0.34) | DPP4OPRM1OPRD1S1PR2S1PR4 | |
| SCHEMBL13069245 | 1.00 | DPP4 (0.34) | DPP4OPRM1OPRD1S1PR2S1PR4 | |
| SCHEMBL4953332 | 1.00 | DPP4 (0.34) | DPP4OPRM1OPRD1S1PR2S1PR4 | |
| SCHEMBL25362077 | 0.87 | GLA (0.33) | DPP4OPRM1OPRD1 | |
| SCHEMBL19914110 | 0.87 | GLA (0.33) | DPP4OPRM1OPRD1 | |
| SCHEMBL13248929 | 0.87 | FUCA1 (0.37) | DPP4S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL16142831 | 0.87 | — | — | |
| SCHEMBL2237799 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL1409661 | 0.84 | DPP4 (0.35) | DPP4OPRM1OPRD1AGLGBA2 | |
| SCHEMBL2902379 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7385064-B1 | Catalysts for use in enantioselective synthesis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-06-10 | — | — | US | disclosed |
| US-7109343-B2 | Metal catalysts and methods for making and using same | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-09-19 | — | — | US | disclosed |
| US-7030051-B2 | Dirhodium catalyst compositions and methods for using same | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-04-18 | — | — | US | disclosed |
| US-6962891-B2 | Solid support dirhodium catalyst compositions and methods for making and using same | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050010049-A1 | Metal catalysts and methods for making and using same | DAVIES HUW M L (US) | 2005-01-13 | — | — | US | disclosed |
| US-6762304-B2 | BIS-TRANSITION METAL CATALYSTS HAVING D2 SYMMETRY | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2004-07-13 | — | — | US | disclosed |
| EP-1173278-B1 | METAL CATALYSTS AND METHODS FOR MAKING AND USING SAME | RES FOUNDATION OFSTATE UNIVERS (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20030130112-A1 | Solid support dirhodium catalyst compositions and methods for making and using same | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2003-07-10 | — | — | US | disclosed |
| US-20030130536-A1 | Dirhodium catalyst compositions and methods for using same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-10 | — | — | US | disclosed |
| US-20020183535-A1 | Metal catalysts and methods for making and using same | DAVIES HUW M L (US) | 2002-12-05 | — | — | US | disclosed |
| US-6410746-B1 | ORGANOMETALLIC COMPOUND CONTAINING TRANSITION METAL | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183535-A1 | Metal catalysts and methods for making and using same | COMT, SLC6A3, SLC6A2 | DPP4 1699/4885OPRM1 14/4885OPRD1 16/4885 |
| US-20030130112-A1 | Solid support dirhodium catalyst compositions and methods for making and using same | DOHH, DHODH, HDHD5 | DPP4 1922/4885OPRM1 4218/4885OPRD1 3594/4885 |
| US-20030130536-A1 | Dirhodium catalyst compositions and methods for using same | DOHH, DNPH1, NOTUM | DPP4 1112/4885OPRM1 4182/4885OPRD1 2377/4885 |
| US-20050010049-A1 | Metal catalysts and methods for making and using same | SLC6A3, COMT, DRD4 | DPP4 2201/4885OPRM1 8/4885OPRD1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.